Show simple item record

dc.contributor.authorMosa, Rasha
dc.contributor.authorHuang, Lili
dc.contributor.authorLi, Hongzhuo
dc.contributor.authorGrist, Michael
dc.contributor.authorLeRoith, Derek
dc.contributor.authorChen, Chen
dc.date.accessioned2019-09-10T03:38:43Z
dc.date.available2019-09-10T03:38:43Z
dc.date.issued2018
dc.identifier.issn0363-6119en_US
dc.identifier.doi10.1152/ajpregu.00157.2017en_US
dc.identifier.urihttp://hdl.handle.net/10072/387172
dc.description.abstractGhrelin secretion has been associated with increased caloric intake and adiposity. The expressions of ghrelin and its receptor (GHS-R1a) in the pancreas has raised the interest about the role of ghrelin in glucose homeostasis. Most of the studies showed that ghrelin promoted hyperglycemia and inhibited insulin secretion. This raised the interest in using GHS-R1a antagonists as therapeutic targets for type 2 diabetes. Available data of GHS-R antagonists are on a short-term basis. Moreover, the complexity of GHS-R1a signaling makes it difficult to understand the mechanism of action of GHS-R1a antagonists. This study examined the possible effects of long-term treatment with a GHS-R1a antagonist, [D-Lys3]-growth hormone-releasing peptide (GHRP)-6, on glucose homeostasis, food intake, and indirect calorimetric parameters in nonobese diabetic MKR mice. Our results showed that [D-Lys3]-GHRP-6 (200 nmol/mouse) reduced pulsatile growth hormone secretion and body fat mass as expected but worsened glucose and insulin intolerances and increased cumulative food intake unexpectedly. In addition, a significant increase in blood glucose and decreases in plasma insulin and C-peptide levels were observed in MKR mice following long-term [D-Lys3]-GHRP-6 treatment, suggesting a direct inhibition of insulin secretion. Immunofluorescence staining of pancreatic islets showed a proportional increase in somatostatin-positive cells and a decrease in insulin-positive cells in [D-Lys3]-GHRP-6-treated mice. Furthermore, [D-Lys3]-GHRP-6 stimulated food intake on long-term treatment via reduction of proopiomelanocortin gene expression and antagonized GH secretion via reduced growth hormone-releasing hormone gene expression in hypothalamus. These results demonstrate that [D-Lys3]-GHRP-6 is not completely opposite to ghrelin and may not be a treatment option for type 2 diabetes.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherAmerican Physiological Societyen_US
dc.relation.ispartofpagefromR71en_US
dc.relation.ispartofpagetoR83en_US
dc.relation.ispartofissue1en_US
dc.relation.ispartofjournalAmerican Journal of Physiology: Regulatory, Integrative, and Comparative Physiologyen_US
dc.relation.ispartofvolume314en_US
dc.subject.fieldofresearchBiological Sciencesen_US
dc.subject.fieldofresearchMedical and Health Sciencesen_US
dc.subject.fieldofresearchcode06en_US
dc.subject.fieldofresearchcode11en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsPhysiologyen_US
dc.subject.keywordsGHS-R antagonistsen_US
dc.subject.keywordstype 2 diabetesen_US
dc.titleLong-term treatment with the ghrelin receptor antagonist [D-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR miceen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationMosa, R; Huang, L; Li, H; Grist, M; LeRoith, D; Chen, C, Long-term treatment with the ghrelin receptor antagonist [D-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice, American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology, 2018, 314 (1), pp. R71-R83en_US
dc.date.updated2019-09-10T03:34:23Z
gro.hasfulltextNo Full Text
gro.griffith.authorChen, Chen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record